Emerging Issues in AAV-Mediated Gene Therapy

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2018 Jan 13

PMID 29326962

Citations 418

Authors

Pasqualina Colella

Giuseppe Ronzitti

Federico Mingozzi

Affiliations

Soon will be listed here.

Abstract

In recent years, the number of clinical trials in which adeno-associated virus (AAV) vectors have been used for gene transfer has steadily increased. The excellent safety profile, together with the high efficiency of transduction of a broad range of target tissues, has established AAV vectors as the platform of choice for gene therapy. Successful application of the AAV technology has also been achieved in the clinic for a variety of conditions, including coagulation disorders, inherited blindness, and neurodegenerative diseases, among others. Clinical translation of novel and effective "therapeutic products" is, however, a long process that involves several cycles of iterations from bench to bedside that are required to address issues encountered during drug development. For the AAV vector gene transfer technology, several hurdles have emerged in both preclinical studies and clinical trials; addressing these issues will allow in the future to expand the scope of AAV gene transfer as a therapeutic modality for a variety of human diseases. In this review, we will give an overview on the biology of AAV vector, discuss the design of AAV-based gene therapy strategies for applications, and present key achievements and emerging issues in the field. We will use the liver as a model target tissue for gene transfer based on the large amount of data available from preclinical and clinical studies.

Citing Articles

Efforts to Downsize Base Editors for Clinical Applications.

Song B Int J Mol Sci. 2025; 26(5).

PMID: 40076976 PMC: 11900391. DOI: 10.3390/ijms26052357.

High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics.

Xiao Y, Lian X, Sun Y, Sung Y, Vaidya A, Chen Z Nat Mater. 2025; .

PMID: 40021827 DOI: 10.1038/s41563-024-02116-3.

Adeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics.

van Olden R, Lo Bianco C, Dilly K, Savelieva M, Xu S, Tijsma A Mol Ther Methods Clin Dev. 2025; 32(4):101344.

PMID: 40018025 PMC: 11866128. DOI: 10.1016/j.omtm.2024.101344.

Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy.

Zwi-Dantsis L, Mohamed S, Massaro G, Moeendarbary E Viruses. 2025; 17(2).

PMID: 40006994 PMC: 11861813. DOI: 10.3390/v17020239.

Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review.

Kharisova C, Kitaeva K, Solovyeva V, Sufianov A, Sufianova G, Akhmetshin R Biomedicines. 2025; 13(2).

PMID: 40002778 PMC: 11852528. DOI: 10.3390/biomedicines13020365.

References

Finn J, Nichols T, Svoronos N, Merricks E, Bellenger D, Zhou S . The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood. 2012; 120(23):4521-3. PMC: 3512231. DOI: 10.1182/blood-2012-06-440123. View

Davidoff A, Gray J, Ng C, Zhang Y, Zhou J, Spence Y . Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther. 2005; 11(6):875-88. DOI: 10.1016/j.ymthe.2004.12.022. View

Duan D, Yue Y, Yan Z, Yang J, Engelhardt J . Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest. 2000; 105(11):1573-87. PMC: 300848. DOI: 10.1172/JCI8317. View

Mingozzi F, Maus M, Hui D, Sabatino D, Murphy S, Rasko J . CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007; 13(4):419-22. DOI: 10.1038/nm1549. View

Nakai H, Yant S, Storm T, Fuess S, Meuse L, Kay M . Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001; 75(15):6969-76. PMC: 114425. DOI: 10.1128/JVI.75.15.6969-6976.2001. View

Nault J, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G . Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015; 47(10):1187-93. DOI: 10.1038/ng.3389. View

Shen S, Horowitz E, Troupes A, Brown S, Pulicherla N, Samulski R . Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J Biol Chem. 2013; 288(40):28814-23. PMC: 3789977. DOI: 10.1074/jbc.M113.482380. View

Kotin R . Large-scale recombinant adeno-associated virus production. Hum Mol Genet. 2011; 20(R1):R2-6. PMC: 3095058. DOI: 10.1093/hmg/ddr141. View

Bockor L, Bortolussi G, Iaconcig A, Chiaruttini G, Tiribelli C, Giacca M . Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler-Najjar Syndrome Type I. Gene Ther. 2017; 24(10):649-660. DOI: 10.1038/gt.2017.75. View

10.

Nair N, Rincon M, Evens H, Sarcar S, Dastidar S, Samara-Kuko E . Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood. 2014; 123(20):3195-9. PMC: 4023424. DOI: 10.1182/blood-2013-10-534032. View

11.

Wu Z, Sun J, Zhang T, Yin C, Yin F, Van Dyke T . Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther. 2007; 16(2):280-9. DOI: 10.1038/sj.mt.6300355. View

12.

High K . Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia. Trans Am Clin Climatol Assoc. 2003; 114:337-51; discussion 351-2. PMC: 2194524. View

13.

Nakai H, Montini E, Fuess S, Storm T, Grompe M, Kay M . AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. 2003; 34(3):297-302. DOI: 10.1038/ng1179. View

14.

Fields P, Arruda V, Armstrong E, Chu K, Mingozzi F, Hagstrom J . Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther. 2001; 4(3):201-10. DOI: 10.1006/mthe.2001.0441. View

15.

Mount J, Herzog R, Tillson D, Goodman S, Robinson N, McCleland M . Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002; 99(8):2670-6. DOI: 10.1182/blood.v99.8.2670. View

16.

Mingozzi F, Anguela X, Pavani G, Chen Y, Davidson R, Hui D . Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med. 2013; 5(194):194ra92. PMC: 4095828. DOI: 10.1126/scitranslmed.3005795. View

17.

Hosel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P . Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology. 2011; 55(1):287-97. DOI: 10.1002/hep.24625. View

18.

Chandler R, LaFave M, Varshney G, Trivedi N, Carrillo-Carrasco N, Senac J . Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015; 125(2):870-80. PMC: 4319425. DOI: 10.1172/JCI79213. View

19.

Ran F, Cong L, Yan W, Scott D, Gootenberg J, Kriz A . In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015; 520(7546):186-91. PMC: 4393360. DOI: 10.1038/nature14299. View

20.

Barzel A, Paulk N, Shi Y, Huang Y, Chu K, Zhang F . Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature. 2014; 517(7534):360-4. PMC: 4297598. DOI: 10.1038/nature13864. View